These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 25178698)

  • 1. Evaluation of the stability profile of anticancer drugs: A review of Ifosfamide and Mesna regimen for the treatment of metastatic soft tissue sarcoma.
    Salman D; Swinden J; Barton S; Peron JM; Nabhani-Gebara S
    J Oncol Pharm Pract; 2016 Feb; 22(1):86-91. PubMed ID: 25178698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physical and chemical stability of high-dose ifosfamide and mesna for prolonged 14-day continuous infusion.
    Zhang Y; Kawedia JD; Myers AL; McIntyre CM; Anderson PM; Kramer MA; Culotta KS
    J Oncol Pharm Pract; 2014 Feb; 20(1):51-7. PubMed ID: 23512269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients.
    Coriat R; Mir O; Camps S; Ropert S; Billemont B; Leconte M; Larousserie F; Anract P; Alexandre J; Goldwasser F
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):491-5. PubMed ID: 19588140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.
    Mace JR; Keohan ML; Bernardy H; Junge K; Niebch G; Romeis P; Thoma A; Wagner T; Mueller U; Demetri G; Baker LH
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5829-34. PubMed ID: 14676103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma.
    Kushner DM; Webster KD; Belinson JL; Rybicki LA; Kennedy AW; Markman M
    Gynecol Oncol; 2000 Aug; 78(2):221-7. PubMed ID: 10926807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience.
    Benjamin RS; Legha SS; Patel SR; Nicaise C
    Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S174-9. PubMed ID: 8453693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ifosfamide in the treatment of soft tissue sarcomas.
    Connelly EF; Budd GT
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):16-21. PubMed ID: 8677442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ifosfamide in the treatment of soft-tissue sarcomas: experience at the West German Tumor Center, Essen.
    Schütte J; Kellner R; Seeber S
    Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S194-8. PubMed ID: 8453697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stability of ifosfamide in solutions for multiday infusion by external pump.
    Leone L; Comandone A; Oliva C; Bussi P; Goffredo F; Bretti S; Bumma C
    Anticancer Drugs; 1995 Aug; 6(4):604-7. PubMed ID: 7579566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas.
    Yalcin B; Pamir A; Buyukcelik A; Utkan G; Akbulut H; Demirkazik A; Icli F
    Exp Oncol; 2004 Dec; 26(4):320-5. PubMed ID: 15627067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules.
    Antman KH; Elias A; Ryan L
    Semin Oncol; 1990 Apr; 17(2 Suppl 4):68-73. PubMed ID: 2110386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical studies of ifosfamide/mesna at St Jude Children's Research Hospital, 1983-1988.
    Pratt CB; Douglass EC; Etcubanas E; Goren MP; Green AA; Hayes FA; Horowitz ME; Meyer WH; Thompson EI; Wilimas JA
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):51-5. PubMed ID: 2495567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depletion of total cysteine, glutathione, and homocysteine in plasma by ifosfamide/mesna therapy.
    Lauterburg BH; Nguyen T; Hartmann B; Junker E; Küpfer A; Cerny T
    Cancer Chemother Pharmacol; 1994; 35(2):132-6. PubMed ID: 7987989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump.
    Radford JA; Margison JM; Swindell R; Lind MJ; Wilkinson PM; Thatcher N
    J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S154-6. PubMed ID: 1795005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
    Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
    Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ifosfamide combination regimens for soft-tissue sarcoma.
    Stuart-Harris R; Dalley D; Bell DR; Levi J; Simes RJ; Wiltshaw E
    Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S185-8. PubMed ID: 8453695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy.
    Barişta I; Tekuzman G; Yalçin S; Güllü I; Güler N; Ozişik Y; Kars A; Celik I; Türker A; Altundağ K; Zengin N; Uner A; Baltali E; Firat D
    J Surg Oncol; 2000 Jan; 73(1):12-6. PubMed ID: 10649272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) in patients with advanced pulmonary pleomorphic carcinoma.
    Lee J; Jung HA; Kim Y; Choi S; Han J; Choi YL; Lee SH; Ahn JS; Park K; Sun JM
    Lung Cancer; 2018 Aug; 122():160-164. PubMed ID: 30032825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ifosfamide and mesna.
    Schoenike SE; Dana WJ
    Clin Pharm; 1990 Mar; 9(3):179-91. PubMed ID: 2107997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of prolonged ambulatory infusion of Ifosfamide with oral mesna.
    Olver I; Keefe D; Myers M; Caruso D
    Chemotherapy; 2005 May; 51(2-3):142-6. PubMed ID: 15886474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.